Financial News

Bausch + Lomb announce PDUFA date for novel glaucoma candidate latanoprostene bunod

PDUFA date set for August 24, 2017 LAVAL, QUEBEC and SOPHIA ANTIPOLIS, FRANCE – March 20, 2017 – Valeant Pharmaceuticals International, Inc.’s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, and Nicox S.A. (Euronext Paris: FR0013018124, COX) today announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA date…

Read more

Nicox resubmits AC-170 (ZERVIATE) NDA to the U.S. FDA

CGMP issues at the API manufacturer have been resolved NDA resubmitted on March 8, 2017 ZERVIATE as the brand name provisionally approved by the U.S. FDA for AC-170 Sophia Antipolis, France Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced the resubmission of the New Drug Application (NDA) for AC-170, its…

Read more

Nicox to participate at two upcoming investor conferences

Sophia Antipolis, France Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that members of the management team will participate in the following investor conferences in March 2017 in the United States: • Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7 at 9:20 a.m. ET at the…

Read more
More news